STUDIES TO EVALUATE THE POTENTIAL FOR ENVIRONMENTAL&THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY - In vitro immunomodulation

评估环境潜力的研究

基本信息

批准号：
10906728
负责人：
FLORENCE BURLESON
金额：
$ 21.65万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-13 至 2024-08-12
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10906728
关键词：
Allergens Animals Autoimmune Diseases Biological Assay Blinded Chemical Agents Chemicals Code Collaborations Communicable Diseases Contracts Data Data Collection Dermal Development Event Exposure to Food Additives Gene Expression Profiling Hazard Identification Health Health Hazards Hematopoietic Human Human Cell Line Hypersensitivity Immunologic Techniques Immunologics Immunosuppression Immunotoxicology In Vitro Laboratories Measures Methods Molecular National Toxicology Program Neoplasms Peptides Pharmaceutical Preparations Predictive Value Preparation Reporting Research Resistance Skin Structure Techniques Testing Therapeutic Agents Validation Xenobiotics dietary supplements environmental agent exposed human population immune function immune system function immunoregulation immunotoxicity in vitro Model in vitro testing in vivo keratinocyte programs respiratory response screening

项目摘要

In vitro techniques for hazard identification for potential sensitizers have been of increasing importance to the NIEHS. A research collaboration agreement with a commercial vendor was established to assess the utility of the GARDair assay to identify respiratory sensitizers. As an extension of the previously reported agency partner studies where >200 chemicals were evaluated using in vitro methods to assess their potential to induce skin sensitization, NIEHS requested nominations from partner agencies to evaluate the use of an in vitro method to evaluate chemicals for their potential to induce allergic responses in the lung. The GARDair assay uses a gene set that has potential for identifying respiratory sensitizers. Agency partners nominated a total of 100 chemicals to be tested, including known respiratory sensitizers as well as chemicals of unknown potential to induce sensitization. BRT completed procurement of the chemicals in FY23 and the laboratory studies are ongoing. To date, 20 chemicals have passed range finder assays and the main runs are completed. NIEHS funded BRT participation in validation trials for the Electrophilic Allergen Screening Assay (EASA). This assay uses non-protein/peptide probes in a cell-free assessment to measure the ability of a test substance to “react” with biologically important molecules for the identification of electrophilic allergic contact dermatitis hazards. Data collection for these chemicals was completed in FY22 and the study method transfer and validation reports were completed and closed in FY23.

潜在传感器的危害识别的体外技术对NIEH的重要性提高。建立了与商业供应商的研究合作协议，以评估花园评估以识别呼吸传感器的效用。作为先前报道的机构合作伙伴研究的延伸，使用体外方法评估了> 200种化学物质，以评估其诱导皮肤敏感性的潜力，NIEHS要求提名伴侣机构的提名，以评估使用体外方法评估化学物质的潜力，以诱导肺部的过敏反应。 Gardair分析使用具有识别呼吸传感器的潜力的基因集。代理合作伙伴提名了总共进行测试的100种化学物质，包括已知的呼吸传感器以及具有诱导灵敏度潜力的化学物质。 BRT完成了23财年化学品的采购，实验室研究正在进行中。迄今为止，已通过20种化学品通过了范围的发现器分析，并且主要运行已完成。 NIEHS资助了BRT参与亲电的过敏原筛选测定法（EASA）的验证试验。该测定法在无细胞评估中使用非蛋白质/肽问题来测量测试物质与生物学上重要的分子“反应”的能力，以鉴定亲电的过敏性接触性皮炎危害。这些化学品的数据收集在22财年完成，研究方法转移和验证报告在23财年完成并关闭。